| Primary |
| Plasma Cell Myeloma |
40.3% |
| Product Used For Unknown Indication |
34.7% |
| Multiple Myeloma |
7.8% |
| Drug Use For Unknown Indication |
3.0% |
| Prophylaxis |
2.2% |
| Amyloidosis |
1.1% |
| Blood Cholesterol Increased |
1.1% |
| Diabetes Mellitus |
1.1% |
| Hypertension |
1.1% |
| Neuropathy Peripheral |
1.1% |
| Pain |
1.1% |
| Paraproteinaemia |
1.1% |
| Anaemia |
0.7% |
| Renal Failure |
0.7% |
| Supplementation Therapy |
0.7% |
| Antiviral Prophylaxis |
0.4% |
| Blood Cholesterol Abnormal |
0.4% |
| Chronic Obstructive Pulmonary Disease |
0.4% |
| Clostridium Difficile Infection |
0.4% |
| Convulsion |
0.4% |
|
| Plasma Cell Myeloma |
12.0% |
| Vomiting |
9.8% |
| Death |
7.6% |
| Pulmonary Oedema |
7.6% |
| Pyrexia |
6.5% |
| Renal Failure |
6.5% |
| Thrombocytopenia |
6.5% |
| Platelet Count Decreased |
5.4% |
| Pneumonia |
4.3% |
| Tremor |
4.3% |
| Urinary Tract Infection |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Ejection Fraction Decreased |
3.3% |
| Localised Infection |
3.3% |
| Myocardial Infarction |
3.3% |
| Epistaxis |
2.2% |
| Feeling Abnormal |
2.2% |
| Local Swelling |
2.2% |
| Pancytopenia |
2.2% |
| Pleural Effusion |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
31.1% |
| Plasma Cell Myeloma |
21.6% |
| Pain |
8.1% |
| Prophylaxis |
8.1% |
| Renal Failure |
5.4% |
| Supplementation Therapy |
5.4% |
| Amyloidosis |
4.1% |
| Hypertension |
2.7% |
| Neuropathy Peripheral |
2.7% |
| Blood Cholesterol Increased |
1.4% |
| Clostridium Difficile Infection |
1.4% |
| Convulsion |
1.4% |
| Fluid Retention |
1.4% |
| Hiv Infection |
1.4% |
| Neutropenia |
1.4% |
| Prostatomegaly |
1.4% |
| Thrombosis |
1.4% |
|
| Local Swelling |
16.7% |
| Platelet Count Decreased |
16.7% |
| Bone Marrow Necrosis |
8.3% |
| Drug Ineffective |
8.3% |
| Fatigue |
8.3% |
| Infection |
8.3% |
| Pericarditis |
8.3% |
| Thrombosis |
8.3% |
| Urinary Tract Infection |
8.3% |
| Vomiting |
8.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
61.8% |
| Plasma Cell Myeloma |
17.2% |
| Drug Use For Unknown Indication |
4.5% |
| Multiple Myeloma |
3.2% |
| Diabetes Mellitus |
1.3% |
| Infection Prophylaxis |
1.3% |
| Nausea |
1.3% |
| Pain |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Asthenia |
0.6% |
| Deep Vein Thrombosis |
0.6% |
| Dehydration |
0.6% |
| Disease Progression |
0.6% |
| Haemorrhage |
0.6% |
| Increased Appetite |
0.6% |
| Infection |
0.6% |
| Menopause |
0.6% |
| Osteopenia |
0.6% |
| Pancytopenia |
0.6% |
| Plasma Cell Myeloma Recurrent |
0.6% |
|
| Plasma Cell Myeloma |
15.0% |
| Sepsis |
15.0% |
| Renal Failure Acute |
10.0% |
| Death |
5.0% |
| Diverticulitis |
5.0% |
| Haemoglobin Abnormal |
5.0% |
| Liver Function Test Abnormal |
5.0% |
| Neuropathy Peripheral |
5.0% |
| Pneumonia |
5.0% |
| Pulmonary Fibrosis |
5.0% |
| Refractory Cytopenia With Multilineage Dysplasia |
5.0% |
| Spinal Compression Fracture |
5.0% |
| Subarachnoid Haemorrhage |
5.0% |
| Thrombosis |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
|
